Zheng Li

8PUBLICATIONS
0CO-AUTHORS
Metabolic medicineGene and molecular therapyBiologically active moleculesMolecular targetsHypersonic propulsion and hypersonic aerothermodynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 15, 2025
Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Zhiling Liang, Lianru Chen, Zibin Liao

|May 19, 2025
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity.

Lianru Chen, Zhiling Liang, Jianming Mao

|Jan 24, 2025
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease.

Shixuan Jiao, Qiang Ren, Lianru Chen

|Jul 29, 2023
Correction: Li et al. Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling. Molecules 2019, 24, 110.

Huachao Li, Yueming Chen, Jiahao Zhang

|Apr 20, 2023
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.

Qiang Ren, Ya Chen, Zongtao Zhou

|Dec 22, 2021
Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen-induced hepatotoxicity.

Zongyu Cai, Bin Wang, Zongtao Zhou

Pageof 2

Frequent Collaborators